Clinical Trials

InPro 8000 Series Turbidity Sensor

This fiber optic measuring system is based on the backscattered light principle and consequently provides the highest possible performance from low/medium turbidities right through to high suspended particle concentrations.

Octapharma launches phase 3 superiority study for PANS

Octapharma has launched a phase 3, multicenter superiority study to compare the effectiveness of PANZYGA (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome (PANS).

PharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancer

PharmaCyte Biotech has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

Twist Bioscience announces potent SARS-CoV-2 neutralising data from Covid-19 therapeutic antibody programme

Twist Bioscience announced data demonstrating the potent neutralizing effects of multiple potential therapeutic antibodies, both Immunoglobulin G (IgG) antibodies and substantially smaller single domain VHH “nanobodies,” against SARS-CoV-2, the virus that causes Covid-19.

Sanofi, GSK begin phase 1/2 clinical trial of Covid-19 vaccine candidate

French pharmaceutical firm Sanofi and British drugmaker GlaxoSmithKline (GSK) have commenced the phase 1/2 clinical of the Covid-19 adjuvanted recombinant protein-based vaccine candidate.

Clear Creek Bio doses first patient in Covid-19 trial with brequinar

Clear Creek Bio has dosed the first patient in phase 1 clinical study of brequinar in hospitalised patients with Covid-19.

Vir, GSK begin phase 2/3 trial of VIR-7831 as Covid-19 antibody treatment

Vir Biotechnology and GlaxoSmithKline (GSK) have started a phase 2/3 study of VIR-7831 (also known as GSK4182136) as a Covid-19 antibody treatment by dosing the first patient.

Orpheris enrols first patients in phase 2 clinical study evaluating OP-101 for severe Covid-19

Orpheris, a wholly-owned subsidiary of Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in inflammatory, oncology and ocular diseases, today announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hospitalized adults with severe Covid-19.

Celltrion receives Korean MFDS approval to initiate trial of Covid-19 antiviral antibody treatment candidate

Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) has approved the company’s Investigational New Drug (IND) application for a Phase I clinical trial of CT-P59, a COVID-19 antiviral antibody treatment candidate.